蛋白酶体抑制剂筛选模型的建立
被引量：1
Development of a screening assay for proteasome inhibitors
出处
《中国药理学通报》
CAS
CSCD
北大核心
2005年第1期123-124,共2页
Chinese Pharmacological Bulletin
基金
国家重大科技专项"创新药物和中药现代化"中专题"新药筛选及关键技术研究"项目资助课题 (No2002AA2Z3461)
参考文献4
-
1Teicher BA, Ara G, Adams Jet al. The proteasome inhibitor PS-341 in cancer therapy [ J ]. Clin Cancer Res, 1999,5 ( 9 ) : 2638 -45.
-
2Schmidtke G, Kraft R, Schmidt20 S proteasome biogenesis: TheM et al. Analysis of mammalian maturation of beta-subunits is an ordered two-step mechanism involving autocatalysis[ J]. EMBO J1996,15(24) : 6887 -98.
-
3Wilson HL, Aldrich HC, Maupin-Furlow J. Halophilic 2O S proteasomes of the archaeon haloferax volcanii : purification, characterization, and gene sequence analysis [ J]. J Bacteriol, 1999,181(18) :5814 -24.
-
4Lightcap ES, Adams J, Elliott PJ et al, Proteasome inhibition measurements: Clinical application[ J]. Clin Chem,2000,46(5 ) :673-83.
同被引文献14
-
1周永列,吕亚萍,许武林,胡惟孝.连续荧光监测法测定蛋白酶体活性及其在筛选蛋白酶体抑制剂中的应用[J].中国临床药理学与治疗学,2008,13(10):1127-1133. 被引量：4
-
2Cerda-Maira F, Darwin KH. The Mycobacterium tuberculosis proteasome: more than just a barrel-shaped protease. Microbes Infect, 2009, 11(14-15): 1150-1155.
-
3Lin G, Li D, de Carvalho LP, et al. Inhibitors selective for mycobacterial versus human proteasomes. Nature, 2009, 461: 621-626.
-
4Vandal OH, Nathan CF, Ehrt S. Acid resistance in Myeobacterium tuberculosis. J Bacteriol, 2009, 191 : 47144721.
-
5Darwin KH, Ehrt S, Gutien'ez-Ramos JC, et al. The proteasome of Mycobacterium tuberculosis is required for resistance to nitric oxide. Science, 2003, 302: 1963-1966.
-
6Ng VH, Cox JS, Sousa AO, et al. Role of KaIG eatalase- peroxidase in mycobacterlal pathogenesis : countering the phagocyte oxidative burst. Mol Microbiol, 2004, 52: 1291-1302.
-
7Lightcap ES, McCormack TA, Pien CS, et al. Proteasome inhibition measurements: clinical application. Clin Chem, 2000, 46: 673-683.
-
8Nam S, Smith DM, Dou QP. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem, 2001,276: 13322-13330.
-
9Wilson HL, Aldrich HC, Maupin-Furlow J. Halophilic 20S proteasomes of the archaeon Haloferax volcanii: purification, characterization, and gene sequence analysis. J Bacteriol, 1999, 181 : 5814-5824.
-
10Meng L, Mohan R, Kwok BH, et al. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Nad Aeud Sci U S A, 1999, 96: 10403-10408.
-
1曹晓伟,宋明家.端粒酶与肝癌[J].中国煤炭工业医学杂志,2000,3(8):776-778.
-
2高金波.端粒酶与乳腺癌的研究进展[J].国外医学（外科学分册）,1999,26(6):321-322. 被引量：3
-
32009年3月份美国FDA批准的NDA[J].国外药讯,2009(4):7-7.
-
4纪潇朗,于冰,金华,周祥,徐春秀,石玉,李祎亮.EGFR抑制剂细胞磷酸化筛选模型的建立与应用[J].中国医药生物技术,2012,7(2):151-153.
-
5付光新,梁尚争.端粒与端粒酶和口腔颌面部肿瘤[J].泸州医学院学报,2006,29(2):160-162.
-
6林如峰,陆化,沈文怡,刘澎,王永韧,汪承亚,李建勇.蛋白酶体抑制剂PS-341对多发性骨髓瘤间充质干细胞IL-1β表达的影响[J].江苏医药,2006,32(4):337-339. 被引量：3
-
7张亚历,周殿元.肠镜检查在早期大肠癌诊断中的重要作用[J].世界华人消化杂志,2003,11(5):640-642. 被引量：8
-
8严春临,张季,杨树平.7-(3-芳基)丙烯酰氧基-4-甲基香豆素的合成[J].河北北方学院学报（自然科学版）,2007,23(2):17-19.
-
9丁晔.蛋白酶体抑制剂PS—34——治疗骨髓瘤的新方法[J].国外医学（输血及血液学分册）,2002,25(5):405-407. 被引量：1
-
10林如峰,陆化,刘澎,王永韧,沈文怡,费小明,葛峥,汪承亚.蛋白酶体抑制剂PS-341对U266细胞凋亡和多种细胞因子表达影响的研究[J].南京医科大学学报（自然科学版）,2007,27(3):220-223.
